Oncternal Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Oncternal Therapeutics

05/05/2022 22:52

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 20 cents per share.
    * Revenue fell 0.3% to $746.00 thousand from a year ago; 
analysts
expected $525.00 thousand. 
    * Oncternal Therapeutics Inc's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 27.7%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Oncternal Therapeutics Inc shares had fallen by 22.3% this
quarter and lost 52.4% so far this year.
    * The company reported a quarterly loss of $9.9 million.
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 5 at 09:51 p.m.  ​All
figures in US dollars unless otherwise stated